CARDIAC MUSCLE MODELING DURING TREATMENT WITH ALISKIREN IN PATIENTS WITH HEART FAILURE
DOI:
https://doi.org/10.52340/jecm.2025.02.16Keywords:
Aliskiren, Echocardiography, Heart Failure, Valvular regurgitationsAbstract
Background and objectives. The aim of the study was to study the cardiac muscle modeling during treatment with aliskiren in patients with heart failure (HF).
Methods. To assess the treatment effects of aliskiren (follow-up period – 6 months) 60 randomly were selected patients with chronic HF of different classes. They were randomly assigned to the study groups. 55 patients treated with aliskiren (150 mg), and finished the study.
Results. Significant changes have not observed for almost all echocardiographic parameters. Percentage of the patients with mitral valve regurgitations of 3rd and 4th grades were significantly decreased; percentages of the patients with tricuspid valve regurgitations of 2nd and 3rd grades were also decreased significantly.
Conclusion. Based on the evaluation of the effects of 6-month treatment of the HF patients with Aliskiren, it may be concluded that Aliskiren showed better results in terms of reducing valvular regurgitations rather than improvement of echocardiographic parameters. To obtain more strong evidences, it is necessary to continue the study to provide the evidence-based results and conclusions.
Downloads
References
AHA Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2023 Update: A Report From the American Heart Association. Circulation. 2023; 147: e93–e621 (DOI Link: htpps://doi.org/10.1161/CIR.0000000000001123)
Vasan RS, Enserro DM, Beiser AS, Xanthakis V. Lifetime Risk of Heart Failure Among Participants in the Framingham Study. J Am Coll Cardiol. 2022; 79(3): 250-263 (DOI Link: htpps://doi.org/10.1016/j.jacc.2021.10.043)
Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023; 9: e11 (DOI Link: htpps://doi.org/10.15420/cfr.2023.05)
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020; 396: 1204–22 (DOI Link: htpps:// doi.org/10.1016/S0140-6736(20)30925-9)
van Riet EES, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016; 18: 242–52 (DOI Link: htpps:// doi.org/10.1002/ejhf.483)
Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019; 7(10): 862-874. (DOI Link: htpps:// doi.org/10.1016/j.jchf.2019.05.015)
Jia G, Aroor AR, Hill MA, Sowers JR. Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 2018; 72(3): 537-548. (DOI Link: htpps:// doi.org/10.1161/HYPERTENSIONAHA.118.11065)
Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015; 116(6): 960-75 (DOI Link: htpps:// doi.org/10.1161/CIRCRESAHA.116.303587)
Luo Y, Chen Q. Efficacy of aliskiren supplementation for heart failure: a meta-analysis of randomized controlled trials. Herz. 2019; 44(5): 398-404 (DOI Link: htpps://doi.org/10.1007/s00059-018-4679-1)
Zhao Q, Shen J, Lu J, Jiang Q, Wang Y. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews. BMC Cardiovasc Disord. 2020; 20(1):179 (DOI Link: htpps://doi.org/10.1186/s12872-020-01442-z)
Trivedi RK, Polhemus DJ, Li Z, Yoo D, Koiwaya H, Scarborough A, et al. Combined angiotensin receptor-neprilysin inhibitors improve cardiac and vascular function via increased NO bioavailability in heart failure. J Am Heart Assoc. 2018; 7:8268 (DOI Link: htpps://doi.org/10.1161/JAHA.117.008268)
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al.. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019; 322:1077–84 (DOI Link: htpps://doi.org/10.1001/jama.2019.12843)
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018; 36: e12435 (DOI Link: htpps://doi.org/10.1111/1755-5922.12435)
Von Elm E, Altman DG, Egger M. STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457. (DOI Link: https://doi.org/10.1016/S0140-6736(07)61602-X)
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation. 2019; 139(11): 1354-1365 (DOI Link: htpps://doi.org/doi:10.1161/CIRCULATIONAHA.118.037077)
Yenercag M, Arslan U, Dereli S, Coksevim M, Dogdus M, Kaya A. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging. 2021; 37(1):165-173 (DOI Link: htpps://doi.org/10.1007/s10554-020-01973-8)
Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q, Chiang YT, Jhund PS, Abraham WT, Dickstein K, McMurray JJV, Køber L. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail. 2018; 20(1):136-147. doi: 10.1002/ejhf.896.
Swedberg K, Borer JS, Pitt B, Pocock S, Rouleau J. Challenges to datamonitoring committees when regulatory authorities intervene. N Engl J Med. 2016; 374:1580–1584 (DOI Link: htpps://doi.org/10.1056/NEJMsb1601674)
Downloads
Published
How to Cite
Issue
Section
